News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

BASi (BASI) Reports Fiscal 2012 Second Quarter Results



5/11/2012 9:31:28 AM

WEST LAFAYETTE, IN--(Marketwire - May 11, 2012) - Bioanalytical Systems, Inc. (NASDAQ: BASI) (BASi) today announced financial results for the second quarter and first half of fiscal 2012.

"BASi's second quarter results are not indicative of the performance we expect from the company. We are taking a variety of actions on the revenue and cost sides of our business that are designed to position the company for future success, and we are confident that our operating results will improve as a result," said President and CEO Tony Chilton.

"We are committed to our strategy to build on BASi's more than three decades of contract research experience to expand our business with the growing population of small biotech and pharmaceutical companies that have become a major force in new drug discovery, while continuing to develop our historically close relationships with major pharmaceutical clients. Pharmacological services and instrument sales were up in April and early May compared to their run rates at the end of the second quarter, and our marketing initiatives in support of our clients' drug discovery efforts, including the recently launched Discovery Center located in our headquarters facility in West Lafayette, appear to be gaining traction. Demand for toxicology services appears to have bottomed, as we are seeing an increase in requests for quotes for these services, an encouraging and long overdue sign of nascent recovery from the recession that has affected the CRO industry so severely these past few years," Chilton said.

Jacqueline Lemke, who was named Vice President of Finance & CFO in April, said, "We are moving forward as rapidly as possible on the restructuring of our bioanalytical laboratory operations announced in March. The decommissioning of our laboratory in McMinnville, Oregon will be completed this month, and the operations consolidated into our West Lafayette facility. We expect to book a $450,000 charge associated with these actions in the current quarter. We also are evaluating several options to improve the financial performance of our laboratory in Warwickshire, UK, and expect to announce a final decision and an estimate of associated costs, if any, in the next few weeks. We continue to expect this laboratory restructuring program to reduce operating costs by more than $2 million annually.

"Separately, over the next three or four months we are planning to take a variety of steps to reduce operating costs at our West Lafayette and Evansville facilities. We believe we will realize savings of approximately $2.5 million annually from this effort, on top of the savings we anticipate from the laboratory restructuring.

"All told, within the next few months we expect to reduce operating costs by at least $4.5 million annually, bringing costs into proper alignment with the current pace of our business while enhancing productivity and customer service through improved capacity utilization and more efficient workflow. Together with the improved outlook for revenue Tony mentioned, we expect these cost reductions to position BASi to deliver the growth and consistent profitability we are confident the company is capable of delivering."

Financial Results

For the three months ended March 31, 2012, revenue decreased 17.3% to $6,966,000 compared to $8,423,000 for the second quarter of fiscal 2011. The net loss for the second quarter of fiscal 2012 was $1,884,000, or $0.27 per share, which included pre-tax restructuring charges of $64,000. This compares to net income of $483,000, or $0.10 per share, for the second quarter of fiscal 2011.

For the six months ended March 31, 2012, revenue decreased 12.3% to $14,482,000 from $16,513,000 for the first six months of fiscal 2011. The net loss for the first six months of fiscal 2012 was $3,375,000, or $0.48 per share, which included pre-tax restructuring charges of $64,000. This compares to net income for the first six months of fiscal 2011 of $793,000, or $0.16 per diluted share.

Cash used in operations was $361,000 for this year's first six months compared to cash provided by operations of $1,785,000 for the first six months of fiscal 2011.

At March 31, 2012, BASi reported cash and cash equivalents of $853,000, total long-term obligations of $1,051,000, and shareholders' equity of $12,395,000, or $1.74 per outstanding share. Current liabilities at March 31, 2012 included mortgage debt of $6,170,000 that matures in November 2012. The Company intends to refinance this amount in lieu of making balloon payments for the remaining principal balances. At September 30, 2011, cash and cash equivalents were $2,963,000, working capital was $526,000, total long-term obligations were $6,913,000, and shareholders' equity was $15,586,000, or $2.25 per outstanding share.

Earnings Conference Call

BASi has scheduled a conference call at 11:00 a.m. EDT this morning to discuss its results for the quarter. To participate in the call, dial 866.825.3209, passcode #35250387 five minutes before the start of the call. A simultaneous webcast may be accessed from the Investors tab at www.BASInc.com. The webcast will be available for replay after 2:00 p.m. EDT at this same Internet address. For a telephone replay, dial 888.286.8010, passcode #71559788 after 2:00 p.m. EDT.

About Bioanalytical Systems, Inc.

BASi is a pharmaceutical development company providing contract research services and monitoring instruments to the world's leading drug development companies and medical research organizations. The company focuses on developing innovative services and products that increase efficiency and reduce the cost of taking a new drug to market. Visit www.BASinc.com for more about BASi.

This release contains forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market and demand for our products and services, the development, marketing and sales of products and services, changes in technology, industry standards and regulatory standards, and various market and operating risks detailed in the company's filings with the Securities and Exchange Commission.

[SEE BELOW FOR CONDENSED CONSOLIDATED FINANCIAL STATEMENTS]

BIOANALYTICAL SYSTEMS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (In thousands, except per share amounts) (Unaudited) Three Months Ended Six Months Ended March 31, March 31, -------------------- -------------------- 2012 2011 2012 2011 --------- --------- --------- --------- Service revenue $ 5,279 $ 6,446 $ 10,890 $ 12,589 Product revenue 1,687 1,977 3,592 3,924 --------- --------- --------- --------- Total revenue 6,966 8,423 14,482 16,513 Cost of service revenue 5,066 4,833 10,322 9,501 Cost of product revenue 757 793 1,535 1,499 --------- --------- --------- --------- Total cost of revenue 5,823 5,626 11,857 11,000 Gross profit 1,143 2,797 2,625 5,513 Operating expenses: Selling 996 774 1,994 1,459 Research and development 162 111 340 223 General and administrative 1,626 1,262 3,234 2,643 --------- --------- --------- --------- Total operating expenses 2,784 2,147 5,568 4,325 Restructuring charges 64 -- 64 -- --------- --------- --------- --------- Operating income (loss) (1,705) 650 (3,007) 1,188 Interest expense (179) (168) (368) (403) Other income -- 1 -- 8 --------- --------- --------- --------- Income (loss) before income taxes (1,884) 483 (3,375) 793 Income taxes -- -- -- -- --------- --------- --------- --------- Net income (loss) $ (1,884) $ 483 $ (3,375) $ 793 Other comprehensive income (loss): Foreign currency translation adjustment 23 29 22 13 --------- --------- --------- --------- Comprehensive income (loss) $ (1,861) $ 512 $ (3,353) $ 806 ========= ========= ========= ========= Basic net income (loss) per share $ (0.27) $ 0.10 $ (0.48) $ 0.16 Diluted net income (loss) per share $ (0.27) $ 0.10 $ (0.48) $ 0.16 Weighted common shares outstanding: Basic 7,034 4,915 6,989 4,915 Diluted 7,034 5,080 6,989 5,025 BIOANALYTICAL SYSTEMS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except share amounts) Mar. 31, Sep. 30, 2012 2011 ----------- ----------- (Unaudited) Assets Current assets: Cash and cash equivalents $ 853 $ 2,963 Accounts receivable Trade 3,333 4,073 Unbilled revenues and other 1,315 1,116 Inventories 1,854 1,636 Refundable income taxes 6 -- Prepaid expenses 429 585 ----------- ----------- Total current assets 7,790 10,373 Property and equipment, net 20,329 20,399 Goodwill 1,383 1,383 Intangible assets, net 38 54 Debt issue costs 80 75 Other assets 581 62 ----------- ----------- Total assets $ 29,678 $ 32,346 =========== =========== Liabilities and Shareholders' Equity Current liabilities: Accounts payable $ 2,560 $ 1,764 Accrued expenses 2,134 1,762 Customer advances 3,678 3,571 Income tax accruals 16 56 Revolving line of credit 1,100 1,346 Current portion of capital lease obligation 545 613 Current portion of long-term debt 6,199 735 ----------- ----------- Total current liabilities 16,232 9,847 Capital lease obligation, less current portion 1,051 1,071 Long-term debt, less current portion -- 5,842 Shareholders' equity: Preferred shares, authorized 1,000,000 shares, no par value: 1,935 Series A shares at 1,000 stated value issued and outstanding at March 31, 2012 and 2,135 at September 30, 2011 1,935 2,135 Common shares, no par value: Authorized 19,000,000 shares; 7,124,404 issued and outstanding at March 31, 2012 and 6,945,631 at September 30, 2011 1,743 1,698 Additional paid-in capital 19,725 19,408 Accumulated deficit (11,081) (7,706) Accumulated other comprehensive income 73 51 ----------- ----------- Total shareholders' equity 12,395 15,586 ----------- ----------- Total liabilities and shareholders' equity $ 29,678 $ 32,346 =========== ===========



Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES